CR11537A - Vacuna - Google Patents
VacunaInfo
- Publication number
- CR11537A CR11537A CR11537A CR11537A CR11537A CR 11537 A CR11537 A CR 11537A CR 11537 A CR11537 A CR 11537A CR 11537 A CR11537 A CR 11537A CR 11537 A CR11537 A CR 11537A
- Authority
- CR
- Costa Rica
- Prior art keywords
- viral vector
- vector
- seq
- relates
- malaria
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere a un vector adenovirico de simio deficiente de replicacion C7 que codifica una proteina CS de P. falciparum o un fragmento de la misma, por ejemplo como se muestra en la SEC ID N° 1 o la SEC ID N° 3. La invencion se refiere tambien a procedimientos de preparacion de dicho vector virico y al uso del vector virico en el tratamiento/prevencion de infeccion por la malaria. se describen tambien composiciones, vacunas y kits que comprenden dicho vector virico. En un aspecto, la invencion emplea un vector virico C7 sintetico. El vector virico C7 segun la invencion puede coadministrarse o coformularse con un antigeno de la malaria tal como RTS,S, opcionalmente en presencia de un coadyuvante, por ejemplo, que comprende 3D-MPL y/o una saponina tal como QS21.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99280207P | 2007-12-06 | 2007-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11537A true CR11537A (es) | 2010-08-18 |
Family
ID=40591828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11537A CR11537A (es) | 2007-12-06 | 2010-06-29 | Vacuna |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2227550A2 (es) |
| JP (1) | JP2011505796A (es) |
| KR (1) | KR20100108544A (es) |
| CN (1) | CN101939438A (es) |
| AR (1) | AR069568A1 (es) |
| AU (1) | AU2008333208A1 (es) |
| BR (1) | BRPI0819889A2 (es) |
| CA (1) | CA2707245A1 (es) |
| CL (1) | CL2008003614A1 (es) |
| CO (1) | CO6300795A2 (es) |
| CR (1) | CR11537A (es) |
| DO (1) | DOP2010000164A (es) |
| IL (1) | IL205953A0 (es) |
| MA (1) | MA32003B1 (es) |
| MX (1) | MX2010006207A (es) |
| PE (1) | PE20091106A1 (es) |
| TW (1) | TW200938633A (es) |
| UY (1) | UY31510A1 (es) |
| WO (1) | WO2009071613A2 (es) |
| ZA (1) | ZA201003851B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815872D0 (en) * | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| EA027236B1 (ru) * | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| AU2003285932A1 (en) * | 2002-10-23 | 2004-05-13 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| NZ539813A (en) * | 2002-12-17 | 2008-04-30 | Crucell Holland Bv | A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6 |
| WO2005063805A1 (en) * | 2003-12-23 | 2005-07-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection |
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| EA016648B1 (ru) * | 2004-10-14 | 2012-06-29 | Круселл Холланд Б.В. | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| US9364525B2 (en) * | 2006-07-18 | 2016-06-14 | Glaxosmithkline Biologicals Sa | Vaccines for malaria |
| PL2137210T3 (pl) * | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
-
2008
- 2008-12-04 WO PCT/EP2008/066762 patent/WO2009071613A2/en not_active Ceased
- 2008-12-04 CL CL2008003614A patent/CL2008003614A1/es unknown
- 2008-12-04 JP JP2010536451A patent/JP2011505796A/ja active Pending
- 2008-12-04 TW TW097147198A patent/TW200938633A/zh unknown
- 2008-12-04 CA CA2707245A patent/CA2707245A1/en not_active Abandoned
- 2008-12-04 UY UY31510A patent/UY31510A1/es unknown
- 2008-12-04 MX MX2010006207A patent/MX2010006207A/es not_active Application Discontinuation
- 2008-12-04 AU AU2008333208A patent/AU2008333208A1/en not_active Abandoned
- 2008-12-04 KR KR1020107014859A patent/KR20100108544A/ko not_active Withdrawn
- 2008-12-04 EP EP08857977A patent/EP2227550A2/en not_active Withdrawn
- 2008-12-04 BR BRPI0819889-6A patent/BRPI0819889A2/pt not_active IP Right Cessation
- 2008-12-04 AR ARP080105281A patent/AR069568A1/es not_active Application Discontinuation
- 2008-12-04 CN CN2008801267101A patent/CN101939438A/zh active Pending
- 2008-12-04 PE PE2008002018A patent/PE20091106A1/es not_active Application Discontinuation
-
2010
- 2010-05-25 IL IL205953A patent/IL205953A0/en unknown
- 2010-05-28 ZA ZA2010/03851A patent/ZA201003851B/en unknown
- 2010-06-02 DO DO2010000164A patent/DOP2010000164A/es unknown
- 2010-06-10 CO CO10070274A patent/CO6300795A2/es not_active Application Discontinuation
- 2010-06-29 CR CR11537A patent/CR11537A/es not_active Application Discontinuation
- 2010-07-05 MA MA32991A patent/MA32003B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010006207A (es) | 2010-10-04 |
| AU2008333208A1 (en) | 2009-06-11 |
| IL205953A0 (en) | 2010-11-30 |
| PE20091106A1 (es) | 2009-08-24 |
| ZA201003851B (en) | 2012-11-28 |
| EP2227550A2 (en) | 2010-09-15 |
| BRPI0819889A2 (pt) | 2015-06-16 |
| CN101939438A (zh) | 2011-01-05 |
| JP2011505796A (ja) | 2011-03-03 |
| KR20100108544A (ko) | 2010-10-07 |
| WO2009071613A2 (en) | 2009-06-11 |
| UY31510A1 (es) | 2009-08-03 |
| CL2008003614A1 (es) | 2010-01-15 |
| TW200938633A (en) | 2009-09-16 |
| CA2707245A1 (en) | 2009-06-11 |
| MA32003B1 (fr) | 2011-01-03 |
| CO6300795A2 (es) | 2011-07-21 |
| AR069568A1 (es) | 2010-02-03 |
| DOP2010000164A (es) | 2010-07-31 |
| WO2009071613A3 (en) | 2009-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117673T1 (el) | Ανασυνδυασμενα αντιγονα rsv | |
| TNSN07387A1 (en) | C.perfringens alpha toxoid vaccine | |
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| AR093712A1 (es) | Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento | |
| WO2010115133A8 (en) | Newcastle disease virus vectored avian vaccines | |
| EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
| NZ757882A (en) | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| PE20100658A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL | |
| WO2009072767A3 (en) | A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| WO2007120673A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| PE20130324A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
| PE20080428A1 (es) | Vacunas para la malaria | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| CR11307A (es) | Vacunas | |
| WO2008054535A3 (en) | Novel influenza m2 vaccines | |
| PH12021552477A1 (en) | Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof | |
| IN2012DN02692A (es) | ||
| MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
| CR11537A (es) | Vacuna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |